FDA found Respilon, a Czech OTC drug maker, lacked ingredient identity testing, stability data and process validation.
What happened
FDA reviewed records Respilon submitted after FDA's May 2, 2025 request under section 704(a)(4), which lets FDA ask for records instead of inspecting. The records showed no identity testing for each incoming ingredient, no stability studies for OTC drugs with expiration dates, and no validated manufacturing process or test methods. FDA also said a finished-batch Certificate of Analysis reported "PASSED" without an individual test result.
What FDA found
Respilon did not test each incoming ingredient to verify its identity and did not test each shipment of certain high-risk components for contamination before use.
21 CFR 211.84(d)(1) and 211.84(d)(2)Respilon did not run stability studies to support the expiration dates on its OTC drug products.
21 CFR 211.166(a)Respilon did not validate its manufacturing processes to show they are reproducible and controlled.
21 CFR 211.100(a)Respilon did not validate its test methods or perform microbiological testing for each batch before release.
21 CFR 211.165(e)Respilon's Certificate of Analysis for a finished batch said "PASSED" but gave no individual test result.
21 CFR 211.194(a)
What FDA wants
FDA tells Respilon to correct the violations promptly, respond in writing within 15 working days with corrective actions and prevention plans, and says a qualified consultant should evaluate its operations and do a six-system audit.
Who should pay attention
- brands that buy OTC drugs from this contract manufacturer
- distributors and retailers selling Respilon-made OTC drugs
- companies relying on supplier certificates of analysis for drug ingredients
This is a summary. Read the original letter on fda.gov.